Activity of different phospholipids in attenuating hyperactivity in bladder irritation

BJU International

Volumn 101, Issue 5, 2008, Pages 627-632

  Tyagi, Pradeep ^a,b   Chancellor, Michael ^b   Yoshimura, Naoki ^b   Huang, Leaf ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bladder irritation; Liposomes; Phospholipids; Protamine sulphate

Indexed keywords

1 OLEOYL 2 STEAROYL SN GLYCERO 3 PHOSPHOCHOLINE; 1 PALMITOYL 2 OLEOYL SN GLYCERO 3 PHOSPHOCHOLINE; 1 PALMITOYL 2 OLEOYL SN GLYCERO 3 PHOSPHOSERINE; 1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 1,2 DIPALMITOYL SN GLYCERO 3 PHOSPHOCHOLINE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOCHOLINE; CHOLESTEROL; LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID DERIVATIVE; POTASSIUM CHLORIDE; PROTAMINE SULFATE; UNCLASSIFIED DRUG; URETHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CONTRACTION FREQUENCY; BLADDER DISEASE; BLADDER HYPERACTIVITY; BLADDER INJURY; BLADDER IRRITATION; BLADDER PRESSURE; CONTROLLED STUDY; CYSTOMETRY; DRUG EFFICACY; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; URETHRAL CATHETER; URINARY TRACT FUNCTION; UROTHELIUM;

ANIMALS; CYSTITIS, INTERSTITIAL; FEMALE; LIPOSOMES; MUSCLE CONTRACTION; PHOSPHATIDYLCHOLINES; PHOSPHOLIPIDS; POTASSIUM CHLORIDE; PROTAMINES; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER; URODYNAMICS;

EID: 38849173126     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07334.x     Document Type: Article

References (26)

1. Parsons CL, Greenberger M, Gabal L, Bidair M, Barme G. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J Urol 1998 159 : 1862 7
2. Lavelle JP, Meyers SA, Ruiz WG, Buffington CA, Zeidel ML, Apodaca G. Urothelial pathophysiological changes in feline interstitial cystitis: a human model. Am J Physiol Renal Physiol 2000 278 : F540 53
3. Chelsky MJ, Rosen SI, Knight LC, Maurer AH, Hanno PM, Ruggieri MR. Bladder permeability in interstitial cystitis is similar to that of normal volunteers: direct measurement by transvesical absorption of 99mtechnetium-diethylenetriaminepentaacetic acid. J Urol 1994 151 : 346 9
4. Parsons CL, Koprowski PF. Interstitial cystitis: successful management by increasing urinary voiding intervals. Urology 1991 37 : 207 12
5. Negrete HO, Lavelle JP, Berg J, Lewis SA, Zeidel ML. Permeability properties of the intact mammalian bladder epithelium. Am J Physiol Renal Physiol 1996 271 : F886 94
6. Apodaca G. The uroepithelium: not just a passive barrier. Traffic 2004 5 : 117 28
7. Hill WG, Zeidel ML. Reconstituting the barrier properties of a water-tight epithelial membrane by design of leaflet-specific liposomes. J Biol Chem 2000 275 : 30176 85
8. Fraser MO, Chuang YC, Tyagi P et al. Intravesical liposome administration - a novel treatment for hyperactive bladder in the rat. Urology 2003 61 : 656 63
9. Cetinel S, Ercan F, Sirvanci S, Sehirli O, Ersoy Y, San T, Sener G. The ameliorating effect of melatonin on protamine sulfate induced bladder injury and its relationship to interstitial cystitis. J Urol 2003 169 : 1564 8
10. Amselem S, Gabizon A, Barenholz Y. Optimization and upscaling of doxorubicin-containing liposomes for clinical use. J Pharm Sci 1990 79 : 1045 52
11. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol 1995 13 : 527 37
12. Lavelle J, Meyers S, Ramage R et al. Protamine sulfate-induced cystitis: a model of selective cytodestruction of the urothelium. Urology 2001 57 (Suppl. 1 113
13. Chuang YC, Chancellor MB, Seki S et al. Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. Urology 2003 61 : 664 70
14. Tzan CJ, Berg J, Lewis SA. Effect of protamine sulfate on the permeability properties of the mammalian urinary bladder. J Membr Biol 1993 133 : 227 42
15. Lilly JD, Parsons CL. Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynecol Obstet 1990 171 : 493 6
16. Lewis SA, Berg JR, Kleine TJ. Modulation of epithelial permeability by extracellular macromolecules. Physiol Rev 1995 75 : 561 89
17. Nickel JC, Forrest J, Barkin J, Payne C, Mosbaugh P. Safety and efficacy of up to 900 mg/day polysulfate sodium (elmiron) in patients with interstitial cystitis. Urology 2001 57 (Suppl. 1 122 3
18. Metts JF. Interstitial cystitis: urgency and frequency syndrome. Am Fam Physician 2001 64 : 1199 206
19. Tzan CJ, Berg JR, Lewis SA. Modification of epithelial permeability by cationic polypeptides. Am J Physiol 1993 265 : C1637 47
20. Bellemare F, Rocheleau H. Modulation of noninduced and phorbol ester-induced generation of superoxide anion by free liposomes and liposomes containing dexamethasone. Immunopharmacol Immunotoxicol 1997 19 : 121 34
21. Stein P, Rajasekaran M, Parsons CL. Tamm-Horsfall protein protects urothelial permeability barrier. Urology 2005 66 : 903 7
22. van Minnen LP, Venneman NG, van Dijk JE et al. Cholesterol crystals enhance and phospholipids protect against pancreatitis induced by hydrophobic bile salts: a rat model study. Pancreas 2006 32 : 369 75
23. Nonas S, Miller I, Kawkitinarong K et al. Oxidized phospholipids reduce vascular leak and inflammation in rat model of acute lung injury. Am J Respir Crit Care Med 2006 173 : 1130 8
24. de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 2006 147 (Suppl. 2 S25 40
25. Slater SJ, Kelly MB, Taddeo FJ, Ho C, Rubin E, Stubbs CD. The modulation of protein kinase C activity by membrane lipid bilayer structure. J Biol Chem 1994 269 : 4866 71
26. Stubbs CD, Slater SJ. The effects of non-lamellar forming lipids on membrane protein-lipid interactions. Chem Phys Lipids 1996 81 : 185 95